AKT1 and neoplasm: MIR-494 reduces PTEN expression in MDSCs, subsequently activating AKT, NF-κB, and mammalian target of rapamycin (mTOR) which, in turn, potentiate their immunosuppressive function, thereby supporting tumor growth [76].